- Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized, two-arm, placebo-controlled, participant and investigator-blinded study investigating the efficacy, safety and tolerability of DFV890 in patients with symptomatic knee osteoarthritis
This study is looking into a new medicine, DFV890, for people with knee osteoarthritis. It compares DFV890 to a dummy treatment (placebo) to see if it helps with pain and is safe to use.
For: Knee OsteoarthritisGermany · Spain · Hungary - Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized, placebo-controlled, parallel-group, investigator- and participant-blinded Phase 2a study to investigate the efficacy, safety, and tolerability of DFV890 and MAS825 for inflammatory marker reduction in an adult population with coronary heart disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
This study is testing new medicines, DFV890 and MAS825, for adults with heart disease and a blood condition called CHIP. We want to see if these medicines can lower inflammation and if they are safe. Some people will get a dummy treatment (placebo) for comparison.
For: Atherosclerotic cardiovascular diseaseGermany - Active not recruitingPHASE1
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
This study is looking into a new medicine called DFV890 for adults with certain myeloid diseases, like specific types of MDS, CMML, and CCUS. It aims to find the right dose and see how safe and effective it is.
For: Myeloid DiseasesUnited States · France · Germany